decrease the consequences of treatment. In this analysis, we summarize the program outcomes and provide an economic perspective on implementation and sustainability. The Bridge Program enrolls and assesses patients at the end of cancer treatment using a
Search Results
HSR20-091: Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia
Stephenie Kennedy-Rea, Adrienne Duckworth, Amy Reasinger Allen, and Samaneh Kalirai
CLO21-029: Impact of Comorbidity Patterns on the Outcomes of Older Patients With Diffuse Large B- Cell Lymphoma
Karen Valdés-Díaz, Halbert Hernández-Negrín, Leonel Valdés-Leiva, Diana Martin-Oliva, and Dianelys Pedraza-González
Background: Comorbidity in elderly has made it difficult to manage when they are affected by aggressive non-Hodgkin's lymphoma. This has led to the historical achievement of poor outcomes, hence the analysis of the impact of comorbidity in this
CLO22-060: > 3 Courses of Neo-Adjuvant Chemotherapy (NACT) May Affect Outcomes of Advanced Ovarian Serous Adenocarcinoma Patients
Yunyun Liu, KKL Chan, and Hui Zhou
relapse, indicating that the poorer outcome of patients with NACT>3 may not be caused by chemo-induced resistance. The reason of worse outcomes after more cycles of NACT is still needed to be explored. CLO22-060 Figure 1 CLO22-060 Table 1
QIM20-121: Oncology Nursing Evidenced Practice and Research Committee; Enhancing Continuity and Improving Patient Outcomes Across Oncology Service Lines
Kristen Burns, Archana Shenoy, and Nicole Turkoglu
population, examine policy and nursing practices to better navigate patients through the continuum of oncology care and improve patient outcomes. The purpose is to describe how the formation of an evidence-based practice committee can engage specialized
Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis
Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin
most patients with UCRP are elderly and many have had prior radical nephroureterectomy, the concern for renal toxicity frequently limits the use of these chemotherapeutic regimens. 11 The poor outcomes and significant toxicities associated with first
Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer
Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen
outcome is related primarily to underlying biology or aggressive cytoreduction with or without hyperthermic intraperitoneal chemotherapy is still debated. The role of modern systemic chemotherapy and targeted therapy in early or advanced nonmucinous and
CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer
Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, and David Stenehjem
in ongoing phase III clinical trials. This study aims to understand the prevalence, current treatment patterns and outcomes of HER2-low patients. Methods : This descriptive study analyzed data from a patient tumor registry in the Huntsman Cancer
Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone
Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann
BT + ADT Relative to EBRT Alone Given the significant potential selection bias for EBRT versus BT, IPTW was used to balance covariables that influenced both treatment allocation and outcomes, and weight-adjusted Cox regression was used to
HSR21-076: Valued Outcomes in the Cancer Experience (VOICE™): Developing and Validating a Measure of Patient Experience
Alexandra K. Zaleta, Erica E. Fortune, Melissa F. Miller, Branlyn W. DeRosa, Joanne S. Buzaglo, Karen Hurley, Mitch Golant, Sara Goldberger, Bruce Rapkin, Lillie D. Shockney, Jemeille Ackourey, and Kelly A. Clark
Background: Despite recognition that patient perspectives should inform cancer care, validated measures that meaningfully capture the patient experience across the cancer continuum remain lacking. We developed Valued Outcomes in the Cancer
HSR20-081: The Direct Referral Unit: Clinical Outcomes and Experience With a Specialized Urgent Care Center for Oncology Patients
Christopher D'Avella, Peter Whooley, Emily Milano, Brian Egleston, Martin Edelman, James Helstrom, Kenneth Patrick, and Jessica Bauman
admissions. Fox Chase Cancer Center (FCCC) developed an urgent care center, the direct referral unit (DRU), in 2012. We sought to characterize the experience of the DRU and its impact on clinical outcomes and utilization. Methods: We abstracted data for
